By Fineline Cube The National Drug Alliance Procurement Office, administrator of China’s volume-based procurement (VBP) program, announced the manufacturing suspension of loxoprofen gel patch by Harbin Liqiang Pharmaceutical Co., Ltd., following the company’s failure to fulfill supply obligations as a winning bidder in the 11th round of VBP. The regulatory body has revoked Liqiang Pharma’s winning bid status and imposed an 18-month ban on VBP participation from April 30, 2026, to October 29, 2027, signaling strict enforcement of supply chain reliability requirements in China’s pharmaceutical procurement system.
Regulatory Action Summary
| Parameter | Detail |
|---|---|
| Product Affected | Loxoprofen gel patch (NSAID topical formulation) |
| VBP Round | 11th round of China’s volume-based procurement |
| Company | Harbin Liqiang Pharmaceutical Co., Ltd. |
| Action Taken | Manufacturing suspension and winning bid status revocation |
| Ban Period | April 30, 2026 – October 29, 2027 (18 months) |
| Regulatory Authority | National Drug Alliance Procurement Office |
VBP Program Enforcement Framework
Supply Obligation Requirements
- Contract Compliance: Winning bidders must maintain consistent supply throughout contract period
- Quality Standards: Products must meet pharmacopeial specifications and GMP requirements
- Delivery Timelines: Strict adherence to agreed-upon delivery schedules across participating provinces
- Capacity Assurance: Manufacturers must demonstrate adequate production capacity before bid submission
Penalty Structure for Non-Compliance
- Immediate Suspension: Production halt for affected products upon violation confirmation
- Bid Status Revocation: Loss of preferential market access and guaranteed volume commitments
- Participation Ban: Temporary exclusion from future VBP rounds ranging from 6–24 months
- Reputation Impact: Public disclosure affecting company credibility with healthcare institutions
Market Impact Assessment
Immediate Supply Chain Disruption
- Patient Access: Potential temporary shortage of loxoprofen gel patches in VBP-covered regions
- Alternative Sourcing: Healthcare institutions required to identify substitute NSAID topical formulations
- Price Pressure: Non-VBP alternatives may command premium pricing during supply gap
- Provincial Coordination: Individual provinces managing emergency procurement procedures
Competitive Landscape Shift
- Market Opportunity: Competing manufacturers of topical NSAIDs positioned to capture displaced demand
- VBP Successor: Alternative supplier likely to be designated through emergency procurement mechanisms
- Pricing Dynamics: Potential temporary price increases for non-banned loxoprofen formulations
- Brand Substitution: Increased adoption of alternative NSAID brands including diclofenac and ketoprofen patches
Industry-Wide Implications
VBP Program Credibility
- Enforcement Precedent: Demonstrates zero-tolerance approach to supply chain failures
- Deterrent Effect: Sends strong signal to other manufacturers about compliance expectations
- System Reliability: Reinforces VBP program’s commitment to uninterrupted patient access
- Quality Focus: Emphasizes that lowest-price bidding must be accompanied by supply capability
Manufacturer Risk Management
- Capacity Planning: Companies must conduct thorough production capacity assessments before VBP participation
- Supply Chain Resilience: Need for redundant manufacturing capabilities and raw material security
- Financial Preparedness: Adequate capital reserves to support sustained low-margin VBP operations
- Regulatory Compliance: Enhanced focus on GMP adherence and quality management systems
Strategic Business Consequences for Liqiang Pharma
Financial Impact
- Revenue Loss: Immediate elimination of guaranteed VBP volumes representing significant revenue stream
- Market Share Erosion: Extended absence from China’s largest pharmaceutical procurement channel
- Reputation Damage: Long-term impact on relationships with hospitals and provincial health authorities
- Operational Costs: Fixed costs continuing despite loss of primary revenue source
Recovery Timeline
- Ban Duration: 18-month exclusion represents substantial competitive disadvantage
- Re-entry Requirements: Must demonstrate improved supply chain capabilities for future VBP participation
- Market Rebuilding: Significant investment required to regain institutional trust and market position
- Strategic Repositioning: Potential need to focus on non-VBP segments or international markets
Policy Context and Future Outlook
VBP Program Evolution
- Maturity Phase: China’s VBP program transitioning from expansion to enforcement and optimization
- Quality Emphasis: Increasing focus on supply reliability alongside price competition
- Manufacturer Screening: Enhanced pre-qualification requirements for future bidding rounds
- Monitoring Systems: Implementation of real-time supply chain monitoring and early warning systems
Broader Healthcare System Impact
- Patient Protection: Ensuring continuity of essential medicine access remains paramount
- Cost Control Balance: Maintaining affordability while preventing supply disruptions
- Domestic Industry Development: Encouraging sustainable business models among Chinese pharmaceutical companies
- International Precedent: China’s VBP enforcement approach potentially influencing global procurement policies
Forward-Looking Statements
This brief contains forward-looking statements regarding the impact of regulatory actions, market dynamics, and policy developments. Actual outcomes may vary due to implementation details, competitive responses, and evolving regulatory frameworks.-Fineline Info & Tech